BEIJING FOYOU PHARMA CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.1 CNY | +0.44% |
|
+2.29% | -6.61% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7,358 | 8,275 |
| Enterprise Value (EV) 1 | 4,940 | 5,869 |
| P/E ratio | 14.7 x | 16.9 x |
| Yield | 2.61% | 2.9% |
| Capitalization / Revenue | 2.27 x | 2.48 x |
| EV / Revenue | 1.52 x | 1.76 x |
| EV / EBITDA | 9.93 x | 10.4 x |
| EV / FCF | 14.5 x | -4,737 x |
| FCF Yield | 6.92% | -0.02% |
| Price to Book | 2.32 x | 2.39 x |
| Nbr of stocks (in thousands) | 480,000 | 480,000 |
| Reference price 2 | 15.33 | 17.24 |
| Announcement Date | 4/17/23 | 3/31/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net sales 1 | 2,425 | 2,535 | 2,838 | 3,240 | 3,340 |
| EBITDA 1 | 285.6 | 341.6 | 420.6 | 497.4 | 564.4 |
| EBIT 1 | 243 | 297.3 | 362 | 431.1 | 485.2 |
| Operating Margin | 10.02% | 11.73% | 12.76% | 13.3% | 14.53% |
| Earnings before Tax (EBT) 1 | 246.9 | 299.8 | 369.3 | 485.9 | 549.2 |
| Net income 1 | 218.8 | 262.7 | 318.1 | 438.5 | 488.8 |
| Net margin | 9.02% | 10.36% | 11.21% | 13.53% | 14.64% |
| EPS 2 | 0.6100 | 0.7300 | 0.8800 | 1.040 | 1.020 |
| Free Cash Flow 1 | 81.64 | 96.66 | 281.3 | 341.7 | -1.239 |
| FCF margin | 3.37% | 3.81% | 9.91% | 10.54% | -0.04% |
| FCF Conversion (EBITDA) | 28.59% | 28.3% | 66.87% | 68.69% | - |
| FCF Conversion (Net income) | 37.32% | 36.79% | 88.41% | 77.92% | - |
| Dividend per Share 2 | 0.3000 | 0.3000 | 0.3000 | 0.4000 | 0.5000 |
| Announcement Date | 6/12/22 | 6/12/22 | 6/12/22 | 4/17/23 | 3/31/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 152 | 236 | 397 | 2,418 | 2,407 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | 81.6 | 96.7 | 281 | 342 | -1.24 |
| ROE (net income / shareholders' equity) | 28.7% | 28.5% | 28.7% | 20% | 14.8% |
| ROA (Net income/ Total Assets) | 9.55% | 10.9% | 11.7% | 8.32% | 6.84% |
| Assets 1 | 2,291 | 2,420 | 2,713 | 5,269 | 7,148 |
| Book Value Per Share 2 | 2.360 | 2.790 | 3.380 | 6.610 | 7.230 |
| Cash Flow per Share 2 | 1.290 | 0.7500 | 1.210 | 5.290 | 5.270 |
| Capex 1 | 86.4 | 169 | 193 | 135 | 366 |
| Capex / Sales | 3.56% | 6.66% | 6.8% | 4.18% | 10.96% |
| Announcement Date | 6/12/22 | 6/12/22 | 6/12/22 | 4/17/23 | 3/31/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.61% | 1.04B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- 601089 Stock
- Financials Beijing Foyou Pharma CO.,LTD